
光动力疗法(PDT)作为一种极具前景的癌症治疗方式,以微创、可重复、耐药性低和时空精准度高著称。然而,传统光敏剂存在诸多问题,如脱靶毒性、肿瘤缺氧环境影响疗效,以及在肿瘤部位积累不足或滞留时间短等,这些缺陷严重制约了光动力疗法的治疗效果,尤其是对体积大、浸润性强的实体瘤效果有限。我国大连理工大学精细化工国家重点实验室及辽宁滨海实验室的联合研究团队发表于《Nature Communications》的研究将靶向EGFR的纳米抗体与智能光敏剂偶联,开发出自报告型光动力纳米抗体偶联物(MNB-Pyra Nbs),成功实现“精准递送-实时反馈-长时治疗”三位一体的突破,为大体积肿瘤治疗提供了革命性方案。
No articles created yet
Let’s start working together, today. You can contact us!
Support is Offline
Today is our off day. We are taking some rest and will come back stronger tomorrow
Official support hours
Monday To Friday
From 9:00AM To 6:00PM
Address
Building A, 15th Floor, WHIIID Headquarters, No. 666 Gaoxin Avenue, East Lake New Technology Development Zone, Wuhan City, P.R of China
Call Us now
Email & Social